Company Overview
Cognition Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company dedicated to the discovery and development of small molecule therapeutics designed to target age-related degenerative diseases and disorders affecting the central nervous system and retina. The company functions within the healthcare sector, specifically the biotechnology industry, positioning it as an entity focused on innovative drug development rather than established commercial revenue generation. As a small-cap entity, the company holds a market capitalization of $65.24M, while its annual revenue is listed as N/A, and the employee count is N/A. These valuation and scale metrics indicate that the company is in a pre-revenue or early-stage clinical development phase, where the market cap reflects investor sentiment regarding potential future therapeutic value rather than current operational earnings or a large established workforce.
Financial Health
The company reports a net income of $-23,487,000 and an EBITDA of $-47,763,000, while revenue is recorded as N/A. The absence of revenue figures combined with a net income loss of $23.487M reveals a cost structure where operating expenses significantly exceed any top-line generation, a typical characteristic of clinical-stage biotechs investing heavily in research and development. The free cash flow stands at $-33,171,500, indicating that the company is burning cash to fund its clinical trials and operational activities, which limits immediate financial flexibility but is often necessary for advancing drug candidates toward market approval. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, reflecting a standard accounting treatment for entities with no reported revenue or sales data in their trailing twelve-month period. On the balance sheet, the company holds $36.81M in cash against $331,000 in debt, resulting in a debt-to-equity ratio of 0.97, which suggests a balance sheet that is effectively debt-free regarding interest-bearing obligations despite the ratio calculation. The current ratio is 3.45, indicating a strong position in short-term liquidity where current assets substantially exceed current liabilities, providing a buffer to meet obligations as they come due. Return on Equity is -88.6% and Return on Assets is -76.0%, metrics that reveal management is currently generating negative returns on the capital invested, a expected outcome for a company still in the clinical discovery phase that has not yet achieved commercial product sales.
Valuation Assessment
The trailing twelve-month P/E ratio is N/A due to the lack of net income, while the forward P/E is listed as -1.57, implying that the market is pricing in future losses or that the earnings trajectory is currently negative and not yet profitable. The price-to-book ratio is 1.27, indicating that the market is valuing the company at a 27% premium over its book value, which may reflect optimism regarding the clinical potential of its lead product candidate CT1812. Alternative valuation metrics include a price-to-sales ratio of N/A and an EV/EBITDA of -0.60, suggesting that traditional sales-based or earnings-based multiple comparisons are not applicable in the conventional sense for a pre-revenue entity. The stock has traded between a 52-week high of $3.83 and a 52-week low of $0.22, with the current price context requiring calculation relative to these bounds to determine if the asset is trading near its recent high or deep within its historical range. The beta value is N/A, meaning that volatility data relative to the broader market is not available for this specific small-cap biotechnology stock in the provided dataset.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, preventing a direct comparison of earnings growth speed against revenue growth as the company has not yet generated commercial sales. Since the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, confirming that the firm reinvests all available resources, including its $36.81M cash reserve, into growth initiatives rather than distributing income to shareholders. The overall growth and income profile for Cognition Therapeutics is defined by zero current income generation and a reliance on capital markets or cash reserves to fund operations while pursuing clinical milestones. This reinvestment strategy is standard for clinical-stage biopharmaceuticals, where the primary objective is to advance drug candidates through regulatory approval processes rather than providing immediate income or consistent revenue growth to investors.